Clinical observation of combined transarterial chemoembolization and targeted therapy in postoperative recurrent colorectal cancer with liver metastasis

Table 5 Adverse events

Adverse event	n (%)
TACE-related
Post-embolization syndrome	60 (80)
Transient liver dysfunction	20 (26.7)
Acute kidney injury	5 (6.7)
Targeted therapy-related
Hypertension	30 (40)
Skin rash	20 (26.7)
Fatigue	15 (20)
Severe adverse events (grade 3-4)
Hepatic failure	2 (2.7)
Severe hypertension	3 (4)
Gastrointestinal perforation	1 (1.3)
Management of adverse events
Hospitalization	8 (10.7)
Dose adjustments/discontinuation	12 (16)

TACE: Transarterial chemoembolization.